New Vetter-Ject® syringe closure system for high sensitivity compounds
Press Release | Vetter Pharma International GmbH
JULY 20, 2015
Ravensburg, Germany: – Vetter has launched Vetter-Ject®, a novel closure system for prefilled syringes. The integrated needle syringe system incorporates very low silicon content and secure closure for use with highly sensitive biological and other compounds.
The Vetter-Ject® tamper-evident closure system, combined with an integrated staked needle, supports the product integrity. Vetter also placed high priority on enhanced user convenience when developing the Vetter-Ject® system, which has already gained two prestigious international awards.
Low silicon for highly sensitive compounds
Today’s pharmaceutical and biotech drugs increasingly incorporate sensitive and complex compounds that demand specialized syringe systems. Patient administration of these drugs requires injection systems that provide high protection to product integrity while remaining safe and simple to handle.
Vetter-Ject® incorporates a needle hub and shield closure system that is partly produced by means of a two-component injection molding process of polypropylene and thermoplastic elastomer.
The baked-in siliconization process for the glass barrel reduces the silicon oil content, making Vetter-Ject® particularly suitable for silicon-sensitive drug products. Silicon content of the syringe body can also be adjusted according to customer requirements. Thus, the amount of silicon used; as well as the related particle load, can be reduced by up to 80 per cent, compared with standard siliconization processes applied to conventional syringe systems.
Safety and convenience
Vetter-Ject® is ready-to-use with an integrated needle that is simple to handle and user-friendly. The tamper-evident closure enables that any attempt at opening of the closure system will be immediately and permanently visible to the naked eye. The tamper proofing prevents any undetected removal of needle shield, preventing any potential misuse or reuse.
Vetter-Ject® can be used with a wide range of primary packaging options like different stoppers and glass barrels, which can be customized according to the needs of the drug product.
Vetter also provides complete sterile fill and finish services and assembly, ranging from trays and plunger rod assembly, to auto-injector assembly and final packaging.
“Our patented syringe closure system offers pharmaceutical and biotech companies more options for filling highly sensitive parenteral drugs,” said Tilman Roedle, Director Packaging Development at Vetter.
“Patients and qualified medical personnel now have the advantage of the system’s easy handling and high standards for product safety and integrity,” Roedle added.
Recognizing its novel design, Vetter’s new syringe closure system has already been the recipient of two international awards prior to its launch: the IF Design Award and the Red Dot Design Award.
“The fact that two eminent juries recognize the novel attributes of Vetter-Ject®, clearly demonstrates the full potential of our innovation,” says Thomas Otto, Managing Director at Vetter.
Vetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons and vaccines. Its clientele includes the world’s ten largest pharma/biotech firms.
A full-service provider, Vetter supports products throughout their lifecycles, from preclinical development through global market supply. Through its U.S. and European facilities, Vetter Development Service provides state-of-the-art support for early-stage products, with seamless transfer at Phase III to Vetter Commercial Manufacturing for large-scale production. Vetter employs approximately 3,400 staff across Europe and the United States. Since 2014, Vetter has also operated a representative office in Singapore, increasing its presence in the Asian healthcare markets.
Oskar Gold; Senior Vice President Key Account Management, Marketing / Corporate Communications Vetter Pharma International
Tel: +49 (0)751-3700-4436